

#5

Page 1 of 1

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	ATTY. DOCKET NO. 33700WC005	SERIAL NO. To Be Assigned
	APPLICANT: Scott D. Wilbur	
	FILING DATE December 29, 2000 (Herewith)	GROUP ART UNIT To Be Assigned

U.S. Patent Documents

Examiner Initials		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE, IF APPROPRIATE
XQW	AA	5,310,916	5/10/94	Jacobson et al.			
XQW	AB	5,134,071	7/28/92	Gaetjens			

Foreign Patent Documents

Examiner Initials		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
							YES	NO
XQW	AC	WO 9729114	8/14/97	PCT				
	AD	WO 9604313	2/15/96	PCT				
	AE	WO 8910140	11/2/89	PCT				
	AF	EP 310 361	4/5/89	EPO				
	AG	WO 9302105	2/4/93	PCT				
	AH	EP 0618192	10/5/94	EPO				
XQW	AI	WO 9904820	2/4/99	PCT				

OTHER INFORMATION (Including Author, Title, Date, Pertinent Pages, Etc.)


XQW	AJ	Cover Page of WO00/02051
	AK	Form PCT/IB/308 PCT/SE99/01241
	AL	Form PCT/IPEA/402 PCT/SE99/01241
	AM	International Search Report for PCT/SE99/01241
	AN	PCT Request (Form PCT/RO/101) PCT/SE99/01241
	AO	International Preliminary Examination Report (PCT/IPEA/409)
	AO	Proc. Natl. Acad. Sci., Volume 93, May 1996, Vladimir R. Muzykantov et al., "Immunotargeting of antioxidant enzymes to the pulmonary endothelium", page 5213-5218, see page 5214 and 5217-5218
	AP	Chemical Abstracts, Volume 126, No. 20, 19 May 1997 (Columbus, Ohio), Otusji, Eigo et al., "Decreased renal accumulation of biotinylated chimeric monoclonal antibody-neocarzinostatin conjugate after administration of avidin", the Abstract No. 258425, Cancer Res. 1997, 88 (2), 205-212
XQW	AQ	The Journal of Immunology, Volume 147, No. 1, July 1991, Alison Tutt, "Trispecific F(ab) 3 derivatives that use cooperative signaling via the TCR/CD3 complex and CD2 to activate and redirect resting cytotoxic t cells", page 60 - page 69, see page 2, left column

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

DATE CONSIDERED

11/9/03

Form PTO-1449
(Rev. 7-80)



U.S. Department of Commerce
Patent and Trademark Office

PAGE 1 OF 6

ATTY. DOCKET NO.
033700.005

SERIAL NO.
09/750,280

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANT
Wilbur, et al

FILING DATE
December 29, 2000

GROUP
1625

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE APPROPRIAT
XQW	A	5,474,772 ✓	12/1995	Maddock			
	B	5,541,287 ✓	7/30/96	Yau et al.			
	C	5,578,287 ✓	11/26/96	Theodore, et al.			
	D	5,482,698 ✓	1/9/96	Griffiths			
	E	5,273,743 ✓	12/28/93	Ahlem et al.			
	F	5,739,287 ✓	4/14/98	Wilbur, et al.			
	G	6,083,926 ✓	7/4/00	Morgan, Jr., et al.			
	H	5,840,880 ✓	11/24/98	Morgan, Jr., et al.			
XQW	I	4,877,868 ✓	10/31/89	Reno, et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATIO	
							YES	NO
* XQW	J	EP 0 567 514 B1	11/1993	Europe				
* ↓	K	WO91/01749 ✓	02/1991	PCT				
* XQW	L	AU-B-64268/90 ✓	03/1991	Australia				

OTHER INFORMATION (including author, title, date, pertinent pages, etc.)

* XQW	M ✓	"Radioimmunoscinigraphy with technetium-99m-labelled monoclonal antibody, SM3, in gynaecological cancer," authored by M. Granowska, et al., featured in <i>European Journal of Nuclear Medicine</i> , Vol. 20, No. 6, June 1993, 483-489
*	N ✓	"Radioimaging of Melanoma Using ^{99m} Tc-labeled Fab Fragment Reactive with a High Molecular Weight Melanom Antigen," authored by Lamk M. Lamki, et al., featured in <i>Cancer Research (Suppl.)</i> , 50, February 1, 1990, pp. 904-908s
*	O ✓	"Clinical Studies of Cancer Radioimmunodetection with Carcinoembryonic Antigen Monoclonal Antibody Fragments Labeled with ¹²⁵ I or ^{99m} Tc," authored by David M. Goldenberg, et al., featured in <i>Cancer Research (Suppl.)</i> , 50, February 1, 1990, pp. 909s-921s
*	P ✓	"Clinical Experience with Iodine-123-Iodophenylpentadecanoic Acid," authored by James Corbett, featured in <i>The Journal of Nuclear Medicine</i> , Vol. 35, No. 4 (Suppl), April, 1994, pp. 32S-37S
*	Q ✓	"Preliminary Report of an Ongoing Phase I/II Dose Range, Safety and Efficacy Study of Iodine-123-Phenylpentadecanoic Acid for the Identification of Viable Myocardium," authored by C. Hansen, featured in <i>The Journal of Nuclear Medicine</i> , Vol. 35, No. 4 (Suppl), April, 1994, pp. 38S-42S
*	R ✓	"Localization of Cognitive Operations in the Human Brain," authored by Michael I. Posner, et al., featured in <i>Science</i> , Vol. 240, June 17, 1988, pp.1627-1631
* XQW	S ✓	"Cardiac SPECT with Iodine-123-Labeled Fatty Acids: Evaluation of Myocardial Viability with BMIPP," authore by F.F. (Russ) Knapp, et al., featured in <i>The Journal of Nuclear Medicine</i> , Vol. 36, No. 6, June, 1995, pp. 1022-10

EXAMINER

Samuel Q. Wells

DATE CONSIDERED

1/9/03

* Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

* References to be provided at a later date

RECEIVED

TEC CENTER 16002900
OCT 15 2001

Form PTO-1449 (Rev. 7-80) U.S. Department of Commerce Patent and Trademark Office

ATTY. DOCKET NO. 033700.005

SERIAL NO. 09/750,280

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANT Wilbur, et al

FILING DATE December 29, 2000

GROUP 1625

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE APPROPRIAT

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATIO YES NO

OTHER INFORMATION (including author, title, date, pertinent pages, etc.)

* LQW	T ✓	"Phase I/II Clinical Radioimmunotherapy with an Iodine-131-Labeled Anti-Carcinoembryonic Antigen Murine Monoclonal Antibody IgG," authored by Thomas M. Behr, et al., featured in <i>The Journal of Nuclear Medicine</i> , Vo 38, No. 6 June, 1997, pp. 858-870
* ↓	U ✓	"Phase I Radioimmunotherapy Trial with Iodine-131-CC49 in Metastatic Colon Carcinoma," authored by C.R. Divgi, et al., featured in <i>The Journal of Nuclear Medicine</i> , Vol. 36, No. 4 April, 1995, pp. 586-592
* LQW	V ✓	"Yttrium-90/Indium-111-DOTA-Peptide-Chimeric L6: Pharmacokinetics, Dosimetry and Initial Results in Patient with Incurable Breast Cancer," authored by Sally J. Denardo, et al., featured in <i>Anticancer Research</i> , Vol.17, 1997 pp. 1735-1744
* LQW	W ✓	"Experimental Radiotherapy of Receptor-Positive Human Prostate Adenocarcinoma With ¹⁸⁸ Re-RC-160, A Direct Radiolabeled Somatostatin Analogue," authored by Paul O. Zamora, et al., featured in <i>Int. J. Cancer</i> , Vol. 65, 1996, pp. 214-220
* LQW	X ✓	"Regulation of Tumor Cell Growth: Experimental Approaches and Clinical Oncology -- Somatostatin Analogues Somatostatin-Receptor-Mediated Radiotherapy of Cancer," authored by B. Stolz, et al., featured in <i>Digestion</i> , Vol 57 (suppl 1), 1996, pp. 17-21
*	Y ✓	"ZD2767, an Improved System for Antibody-directed Enzyme Prodrug Therapy That Results in Tumor Regression in Colorectal Tumor Xenografts," authored by David C. Blakey, et al., featured in <i>Cancer Research</i> , Vol.56, July 15, 1996, pp. 3287-3292
*	Z ✓	"Clearance of circulating radio-antibodies using streptavidin or second antibodies in a xenograft model," authored Marshall, et al., featured in <i>Br. J. Cancer</i> , Vol. 69, 1994, pp. 502-507
*	AA ✓	"Immunotargeting of antioxidant enzymes to the pulmonary endothelium," authored by Vladimir R. Muzykantov, al., featured in <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 93, May 1996, pp. 5213-5218
*	AB	"Development of a Streptavidin - Anti-Carcinoembryonic antigen, Antibody, Radiolabeled Biotin Pretargeting Method for Radioimmunotherapy of Colorectal Cancer. Studies in a Human Colon Cancer Xenograft Model," authored by Robert M. Sharkey, et al., featured in <i>Bioconjugate Chem.</i> , Vol. 8, No. 4, 1997, pp. 595-604
*	AC	"Rapid Blood Clearance of Biotinylated IgG after Infusion of Avidin," authored by Vladimir V. Sinitsyn, et al., featured in <i>The Journal of Nuclear Medicine</i> , Vol. 30, No. 1, January, 1989, pp. 66-69
*	AD	"Galactosylated streptavidin for improved clearance of biotinylated intact and F(ab) ₂ fragments of an anti-tumour antibody," authored by D. Marshall, et al., featured in <i>British Journal of Cancer</i> , Vol. 71, 1995, pp. 18-24
*	AE	"The Role of Surface Carbohydrates in the Hepatic Recognition and Transport of Circulating Glycoproteins," authored by Gilbert Ashwell, et al., featured in <i>Adv. Enzymol</i> , Vol. 41, 1974, pp. 99-128 (Ref Missing)
* LQW	AF	"Strategies to Enhance the Localization of Anticancer Immunoconjugates," authored by George J. Schreiber, et al. featured in <i>Current Medicinal Chemistry</i> , Vol. 2, 1995, pp. 616-629
	AG	"Improved Monoclonal Antibody Tumor/Background Ratios with Exchange Transfusions," authored by Christine Henry, et al., featured in <i>Nucl. Med. Biol.</i> Vol. 18, No. 5, 1991, pp. 565-567

EXAMINER
Laura Q. Welch

DATE CONSIDERED
1/9/03

* Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

* References to be provided at a later date

Form PTO-1449
(Rev. 7-80)U.S. Department of Commerce
Patent and Trademark OfficeATTY. DOCKET NO.
033700.005SERIAL NO.
09/750,280

INFORMATION DISCLOSURE STATEMENT

(Check several sheets if necessary)

APPLICANT
Wilbur, et alFILING DATE
December 29, 2000GROUP
1625

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE APPROPRIAT

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATIO YES NO

OTHER INFORMATION (including author, title, date, pertinent pages, etc.)

* <i>LQW</i>	AI✓	"Clinical Aspects of Local and Regional Tumor Therapy with ¹⁸⁸ Re-RC-160," authored by H. Bender, et al., featur in <i>Anticancer Research</i> , Vol.17, 1997, pp. 1705-1712
*	AI✓	"Blood Clearance of Radiolabeled Antibody: Enhancement by Lactosamination and Treatment with Biotin-Avidin Anti-Mouse IgG Antibodies," authored by Alexander L. Klibanov, et al., featured in <i>The Journal of Nuclear Medicine</i> , Vol. 29, No. 12, December, 1998, pp. 1951-1956
*	AJ✓	"Improved Characteristics of a Human β -Glucuronidase-Antibody Conjugate after Deglycosylation for Use in Antibody-Directed Enzyme Prodrug Therapy," authored by Pieter H. J. Houba, et al., featured in <i>Bioconjugate Chem.</i> , Vol. 7, No. 5, 1996, pp. 606-611
*	AK✓	"Site-Specific Prodrug Activation by Antibody- β -Lactamase Conjugates: Preclinical Investigation of the Efficacy and Toxicity of Doxorubicin Delivered by Antibody Directed Catalysis," authored by Damon L. Meyer, et al., featured in <i>Bioconjugate Chem.</i> , Vol. 6, No. 4, 1995, pp. 440-446
*	AL✓	"Avidin and Streptavidin," authored by N. Michael Green, featured in <i>Methods in Enzymology</i> , Vol. 184, 1990, pp 51-67
* <i>LQW</i>	AM✓	"Avidin," authored by N. Michael Green, featured in <i>Adv. Prot. Chem.</i> , Vol. 29, 1975, pp. 85-132.
	AN	
	AO	
	AP	
	AQ	
	AR	
	AS	
	AT	
	AU	
	AV	

EXAMINER

LQW


DATE CONSIDERED

1/9/03

* Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

* References to be provided at a later date

Form PTO-1449
(Rev. 7-80)



U.S. Department of Commerce
Patent and Trademark Office

PAGE 4 OF 6

ATTY. DOCKET NO.
033700.005

SERIAL NO.
09/750,280

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANT

WILBUR, et al.

FILING DATE

December 29, 2000

GROUP

1625

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
						RECEIVED
						OCT 15 2001
						TECH CENTER 1600/290

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER INFORMATION (including author, title, date, pertinent pages, etc.)

*	BA	"Plasma Stability and Pharmacokinetics of Radiolabeled Deferoxamine-Biotin Derivatives," authored by Scott F. Rosebrough, featured in <i>The Journal of Pharmacology and Experimental Therapeutics</i> , Vol. 265, No. 1, 1993, pp. 408-415
*	BB	"Scientific Papers - Proceedings of the 39 th Annual Meeting (Wednesday)," featured in <i>The Journal of Nuclear Medicine</i> , Vol. 33, No. 5, May, 1992, pp. 862-864
*	BC	"Immunology," featured in <i>Proceedings of AACR</i> , Vol. 28, March 1987, p. 391
*	BD	"Decreased renal accumulation of biotinylated chimeric monoclonal antibody-neocarzinostatin conjugate after administration of avidin", authored by Otusji, et al., featured as an ABSTRACT in the American Chemical Society, 1998, p. 1
*	BE	"Radiolabeling of Monoclonal Antibodies with Metal Chelates," featured in <i>Pure & Appl. Chem.</i> , Vol. 63, No. 3, 1991, pp. 427-463

EXAMINER

* References to be provided at a later date

DATE CONSIDERED

1/9/03

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

Form PTO-1449
(Rev. 7-80)

U.S. Department of Commerce
Patent and Trademark Office

ATTY. DOCKET NO.
033700.005

SERIAL NO.
09/750,280

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANT

WILBUR, et al.

FILING DATE

December 29, 2000

GROUP

1625

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

RECEIVED

OCT 15 2001

TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
					YES	NO

OTHER INFORMATION (including author, title, date, pertinent pages, etc.)

* LQW	AU	"Extracorporeal Immunoabsorption From Whole-Blood Based on the Avidin-Biotin Concept Evaluation of a New Method," authored by Michael Garkavij, et al., featured in <i>Acta Oncologica</i> , Vol. 35, No. 3, 1996, pp. 309-312
*	AV	"Evaluation of Extracorporeal Immunoabsorption for Reduction of the Blood Background in Diagnostic and Therapeutic Applications of Radiolabeled Monoclonal Antibodies" authored by Kristina Norrgren, et al., featured in <i>Antibody, Immunoconjugates, and Radiopharmaceuticals</i> , Vol. 4, No. 4, 1991, pp. 907-914
*	AW	<i>Radionuclides in Therapy</i> , edited by Richard P. Spencer, et al., 1987 (Table of Contents included)
*	AX	"Radionuclide Production for the Biosciences," authored by T.J. Ruth, et al., featured in <i>Nucl. Med. Biol.</i> , Vol. 16, No. 4, 1989, pp. 323-336
*	AY	"Biotinidase," authored by Barry Wolf, et al., featured in <i>Methods in Enzymology</i> , Vol. 184, 1990, pp. 103-111
* LQW	AZ	"Animal Biotinidase," authored by Jaakko Pispä, featured in <i>Annales Medicinæ Experimentalis Et Biologiæ Fenniae</i> , Vol. 43, 1965, Suppl. 5, pp. 1-39

EXAMINER

* References to be provided at a later date

DATE CONSIDERED


1/4/03

* Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

Form PTO-1449
(Rev. 7-80)

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)



U.S. Department of Commerce
Patent and Trademark Office

PAGE 6 OF 6

ATTY. DOCKET NO.

033700.00:5

SERIAL NO.

09/750,280

APPLICANT

WILBUR, et al.

FILING DATE

December 29, 2000

GROUP

1625

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
						RECEIVED
						OCT 15 2001
						TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER INFORMATION (including author, title, date, pertinent pages, etc.)

* XQW	AN	"Improved Tumor Imaging with Radiolabeled Monoclonal Antibodies by Plasma Clearance of Unbound Antibody with Anti-antibody Column," authored by James L. Lear, MD, et al., featured in <i>Radiology</i> , Vol. 179, 1991, pp. 509-512
*	AO	"Radioimmunoabsorption of KC-4G3 Antibody in Peripheral Blood: Implications for Radioimmunotherapy," authored by Timothy K. Johnson, et al., featured in <i>Antibody, Immunoconjugates, and Radiopharmaceuticals</i> , Vol. 4, No. 4, 1991, pp. 885-893
*	AP	"Extracorporeal Immunoabsorption of Radiolabeled Monoclonal Antibody: A method for Reduction of Background Radioactivity and Its Potential Role During the Radioimmunotherapy of Cancer," authored by David G. Dienhart, et al., featured in <i>Antibody, Immunoconjugates, and Radiopharmaceuticals</i> , Vol. 7, No. 4, 1994, pp. 225-252
*	AQ	"Immunoabsorption: An Enhancement Strategy for Radioimmunotherapy," authored by Gerald L. DeNardo, et al., featured in <i>The Journal of Nuclear Medicine</i> , Vol. 34, No. 6, June, 1993, pp. 1020-1027
*	AR	"Biotin Reagents for Antibody Pretargeting. Synthesis, Radioiodination, and in Vitro Evaluation of Water Soluble, Biotinidase Resistant Biotin Derivatives," authored by D. Scott Wilbur, et al., featured in <i>Bioconjugate Chem.</i> , Vol. 8, 1997, pp. 572-584
*	AS	"A General, Extracorporeal Immunoabsorption Method to Increase the Tumor-to-Normal Tissue Ratio in Radioimmunotherapy," authored by Kristina Norrgren, et al., featured in <i>The Journal of Nuclear Medicine</i> , Vol. 34, No. 3, March, 1993, pp. 448-454
* XQW	AT	"Extracorporeal Whole-Blood Immunoabsorption Enhances Radioimmunotargeting of Iodine-125-Labeled BR96-Biotin Monoclonal Antibody," authored Michael Garkavij, et al., featured in <i>The Journal of Nuclear Medicine</i> , Vol. 38, No. 6, June, 1997, pp. 895-901

EXAMINER

* References to be provided at a later date

Ramon Q. Wells

DATE CONSIDERED

1/9/03

* Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.